About Genesis Molecular AI
Genesis Molecular AI (formerly Genesis Therapeutics) pairs frontier AI researchers with world-class drug hunters to discover small molecule medicines using its GEMS (Genesis Exploration of Molecular Space) AI platform. GEMS integrates generative and predictive AI with physical simulation to generate and optimize drug molecules, including the breakthrough diffusion model Pearl for protein-ligand structure prediction. The company partners with major pharma firms including Incyte and Gilead, and also pursues its own internal drug discovery pipeline.
Company details
Funding
Total raised
$308.7M
Last stage
Series B
Investors
Founders
Vijay Pande
Vijay Pande, PhD, is the Stanford University professor whose lab Genesis Therapeutics spun out from, focusing on machine learning-powered simulations in chemistry, biology, and medicine.
Evan Feinberg
Evan Feinberg, PhD, co-founded Genesis Therapeutics and co-authored key peer-reviewed papers on deep learning technologies for drug discovery. He leads the company in pioneering AI for structure-driven drug design.
LinkedInBen Sklaroff
Co-founded Genesis Therapeutics alongside Evan Feinberg in 2019.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.